)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Veracyte
Veracyte (VCYT) investor relations material
Veracyte Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary25 Feb, 2026
Executive summary
Achieved strong double-digit revenue growth in Q4 and full year 2025, driven by Decipher and Afirma test performance, with Q4 revenue reaching $141 million (up 19%) and full-year revenue at $517 million (up 16%).
Surpassed profitability targets ahead of schedule, with adjusted EBITDA margin exceeding 27% for 2025 and Q4 margin at 30.1%.
Served nearly 170,000 patients in 2025 and over 800,000 to date, with over 45,000 patients served in Q4.
Achieved all 2025 milestones, including Decipher Metastatic launch, Afirma transition to v2 transcriptome, and significant clinical evidence generation.
Positioned for multiple product launches in 2026, including TruMRD for muscle-invasive bladder cancer and Prosigna for early-stage breast cancer.
Financial highlights
Q4 2025 revenue was $140.6–$141 million, up 19% year-over-year; testing revenue up 21% to $135.8–$136 million; total test volume ~48,000, up 16%.
Full-year 2025 revenue reached $517–$517.1 million, up 16%; testing revenue up 18% to $493.2 million.
Q4 GAAP net income: $41.1 million; full-year GAAP net income: $66.4 million; Q4 adjusted EBITDA: $42.3 million (30.1% margin); full-year adjusted EBITDA: $142.5 million (27.6% margin).
Q4 non-GAAP gross margin: 75.1%; full-year non-GAAP gross margin: 72.9%.
Ended Q4 with $412.9 million in cash and cash equivalents, up over $120 million for the year.
Outlook and guidance
2026 revenue guidance: $570–$582 million (10–13% growth); testing revenue guidance: $560–$570 million (14–16% growth), excluding new test contributions.
Adjusted EBITDA margin guidance for 2026: ~25%, with Q1 margin expected to be lower due to seasonality.
Afirma growth expected in mid to high single digits; Decipher growth projected at ~20%.
Guidance excludes PPCs; $10 million PPC headwind expected in 2026.
New product launches (TruMRD, Prosigna) not included in 2026 revenue guidance; expected to drive revenue in 2027 and beyond.
2026 new test revenue contribution outlook?
Why 2026 adjusted EBITDA margin decline?
Is Veracyte SAS restructuring impact fully past?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Veracyte earnings date
47th Annual Raymond James Institutional Investor Conference3 Mar, 2026
Veracyte
Next Veracyte earnings date
47th Annual Raymond James Institutional Investor Conference3 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Veracyte, Inc. develops and commercializes blood tests for the early detection of lung cancer and emphysema. The company offers Veracyte Drug Screening Assay and Veracyte Acute Exacerbation Panel (V-AEP) for the detection of Lung Cancer and Chronic Obstructive Pulmonary Disease (COPD). Its drug screening assays are based on a proprietary approach of analyzing patient genomic data to predict which patients are most likely to have cancer after receiving a lung CT scan. The company markets its products through direct sales force, as well as through clinical laboratory partners, medical practitioners, and directly to patients.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage